Although advances have been made in the treatment of both type 1 and 2 diabetes, many patients still do not achieve sufficient glycaemic control. The reasons behind this are multifactorial, but post‑prandial hyperglycaemia is likely an important contributing factor.
Insulin formulations with a more rapid onset of action, along with appropriate timing of insulin use and post‑prandial glucose (PPG) monitoring, may offer potential options to improve PPG levels. A novel formulation of insulin lispro, ultra‑rapid lispro (URLi), was studied in two randomized, double‑blind, multicentre, international phase 3 trials: PRONTO‑T1D, in patients with type 1 diabetes (T1D), and PRONTO‑T2D, in patients with type 2 diabetes (T2D).…
